PCN221 Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy: Qualitative Analyses of Early Post-Treatment Interviews With Relapsed and Refractory Multiple Myeloma (RRMM) Patients in the KarMMa Clinical Trial
Jun 1, 2021, 00:00
10.1016/j.jval.2021.04.311
https://www.valueinhealthjournal.com/article/S1098-3015(21)00528-3/fulltext
Title :
PCN221 Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy: Qualitative Analyses of Early Post-Treatment Interviews With Relapsed and Refractory Multiple Myeloma (RRMM) Patients in the KarMMa Clinical Trial
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(21)00528-3&doi=10.1016/j.jval.2021.04.311
First page :
Section Title :
Open access? :
No
Section Order :
10889